Summary
The U.S. Food and Drug Administration has lifted its hold on a clinical trial for Cloretazine, an anticancer agent being developed by Vion Pharmaceuticals Inc., which is based in Science Park.
The FDA suspended enrollment and treatment in the clinical trial last May after the administration's review of the trial raised questions about the trial's quality and integrity.See the full content of this document
Extract
Fda Lifts Hold On Vion Drug Trial
An FDA spokeswoman said the administration does not comment on drug trials until the drug is ...
See the full content of this document
Sponsored links
